MODEL SPOTLIGHT | Modeling Human Acute Lymphoblastic Leukemia (ALL)
Using the NALM6-Luc-mCh-Puro Model for the Development of CAR T Cell Therapies
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid lineage characterized by the development of increased numbers of immature lymphocytes. ALL is a relatively rare cancer; however, it is the most common childhood cancer, which makes it of interest to researchers. Standard therapies for ALL include the use of aggressive or long-term chemotherapy. These treatment regimens result in 90% of children surviving after five years, but this drops to around 40% of adult patients remaining disease free. Due to this relapse rate, other treatment options have been sought.
In recent years, CAR T cells for ALL have been approved for commercial use, however, there is a need for new models that will help in the development of a next generation of therapies. In our model spotlight this month we talk about our in-house establishment of NALM6-Luc-mCh-Puro in NSG mice as a model for ALL and show data on its growth kinetics and survival times. Learn more about this model by reading the full article.